Figure 3.

Identification of Carrier Cells from Autologous Donor BM and PBMC Compartments to Transfer MYXV into Myeloma Tumor Sites

(A) Schematic overview of the experimental workflow including the treatment timeline of the experimental cohorts using NOD/SCID-γ donors of BM or PBMCs. All samples except for the non transplant controls (cohort I) were incubated with MYXV for 1 h at 37°C prior to transplantation to allow virus adsorption. “+neutrophils” refers to enriched neutrophil samples isolated from BM, whereas “BM−neutrophils” refers to BM samples depleted of neutrophils. (B) Kaplan-Meier survival curves in days after cancer implantation. (C) Flow cytometry plots showing the myeloma tumor burden from target organs such as BM, spleen, and solid tumors. Error bars correspond to the Mean ± SD of tumor burden of representative mice. p values are reported as non significant (ns) if p > 0.05, and significant if ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p ≤ 0.0001.